Robert L. Moore, Ph.D., Senior Director of Business Development for North AmericaComplex therapies move forward when chemistry is mastered at scale. For organizations accountable for delivering safe, scalable, and compliant therapies, progress depends on deep process understanding, consistent quality controls, and scientist-led teams who stay connected as programs grow. For chronic disease and oncology programs, a streamlined workflow from development to manufacturing ensures timelines stay on track and risks remain under control.
Realizing that principle in practice is Tianyu Pharm, a contract development and manufacturing organization (CDMO) that produces key intermediates and APIs while controlling every stage, from raw starting materials to production. Building over three decades of trust with global pharmaceutical and biotechnology partners, the company empowers its scientist-led teams with structured project management to innovate, optimize processes, and deliver reliable solutions.
“Our scientist-led approach empowers specialized teams, drives process development, and delivers consistent, high-quality results for our clients,” says Robert L. Moore, Ph.D., Senior Director of Business Development.
At Tianyu, chemists do not hand off their work when a process leaves the lab. They develop the reactions and guide the process through scale-up and commercial manufacturing, applying their insights at every step. Additionally, the engineering team is involved at every step of process development, ensuring that the physical infrastructure aligns with the chemistry to further ensure quality and cost-effectiveness of manufacturing at scale. With a stable workforce of more than 4,000 employees and over 200 PhDs and Master’s leading process development and scale-up, the company integrates scientific ownership into every stage of production. It maintains stable production teams across long-term development programs, with approximately 95 percent annual employee retention.
Tianyu operates six specialized R&D laboratories, each focused on specific areas, including enzymatic chemistry, continuous-flow chemistry, and advanced process development. By keeping teams compact and highly focused, as well as ensuring that the leaders and 60% of the total R&D staff have clinical and commercial production experience, the company enables scientists to advance complex chemistries and explore emerging modalities, while maintaining full ownership of the process. Equipped with cutting-edge instruments, pilot-scale production lines, enzyme libraries, and fully integrated analytical labs, these teams ensure that every innovation moves effortlessly into manufacturing, reducing risk and preserving quality.
Quality Embedded into Every Step
How are quality assurance systems integrated into every stage of pharmaceutical manufacturing?
Tianyu maintains one of its largest fully integrated teams in quality assurance (QA) and quality control (QC), with approximately one QA/QC professional supporting every seven production staff. Each of its five manufacturing sites has 60,000 square feet dedicated to QA and QC laboratories equipped with mass spectrometry, HPLC, GC, and advanced analytical systems. That embedded oversight enables programs to progress with the speed, reliability, and capacity required in drug development.
For chronic disease and oncology programs, the company employs a development model that prioritizes early process optimization in non-GMP environments. This approach allows teams to explore alternatives and establish a reliable, efficient, sustainable, and cost-effective process before scale-up begins. As the scientists who develop processes during R&D transition into manufacturing, they preserve knowledge, streamline tech transfer, de-risk scale-up, and maintain strong alignment with client objectives.
“When we take on a project, we stabilize the right solution early and function as an integral part of our clients’ teams rather than a contractor,” says Moore. That responsibility does not end at development; it defines how manufacturing is executed, prioritizing long-term partnerships with its clients.
-
Our scientist-led approach empowers specialized teams, drives process development, and delivers consistent, high-quality results for our clients.
“When we take on a project, we stabilize the right solution early and function as an integral part of our clients’ teams rather than a contractor,” says Moore. That responsibility does not end at development; it defines how manufacturing is executed, prioritizing long-term partnerships with its clients.
Across all operations, Tianyu integrates digital manufacturing control systems with real-time monitoring and closed-loop production wherever possible. Continuous sampling, as well as analytical method and process optimization, allow deviations to be identified early, preventing batch loss and preserving material value. Clearly defined SOPs empower teams to pause, correct, and resume processes with precision instead of reactively managing failures.
Advanced manufacturing strategies further strengthen scalability. Continuous flow chemistry has become the company’s core competency, improving efficiency, consistency, and sustainability. Reagent recovery rates of up to 95 percent for precious-metal catalysts simultaneously reduce costs and environmental impact. These optimizations ensure scalability is volumetric and economically viable as programs grow.
By producing raw starting materials and intermediates internally, Tianyu strengthens reliability across its manufacturing network rather than relying solely on external sourcing. The company reinforces its risk-mitigation strategy and reduces its dependence on external factors by controlling material quality from the source to the finished API. Redundancy is built into each site through multiple workshops and production lines, while specialized capabilities across five facilities allow capacity and technical expertise to be deployed where needed. Temperature-controlled storage exceeding 30,000 square meters at each of the five production sites, along with established logistics networks, support uninterrupted supply for global drug developers.
Tianyu’s total reactor capacity exceeds 8.1 million liters, supporting projects ranging from 100-liter clinical batches to 10,000-liter commercial runs and tens of metric tons annually. The company’s recent investments include a 24,000-square-foot OEB 4 high-potency workshop capable of handling reactions from 100 liters to 4,000 liters, alongside expansion into peptides, ADC linkers, and payloads. These manufacturing capabilities form the backbone for sustained commercial production in highly regulated global markets.
Proven Compliance across Borders
How does Tianyu maintain regulatory compliance across global pharmaceutical manufacturing markets?
Operating at such a scale, facilities are subject to ongoing inspections by global regulatory authorities. Tianyu has undergone audits by major global authorities, including the FDA, EMA, NMPA, and regulators across Japan, Brazil, Australia, and Korea. A recent FDA audit conducted in November 2024 concluded with no major findings, underscoring the rigor embedded in the company’s quality systems. With more than 200 active clients and frequent regulatory and customer audits, its compliance processes are continuously exercised and refined.
Tianyu holds drug master files in over 51 countries and supplies intermediates and APIs for the production of more than 50 medicines in China, with plans to expand to the EU, Japan, as well as emerging markets, including West Africa and beyond. Within hypotensive, hypoglycemic, and anti-tumor categories, the company leverages these refinements to enhance efficiency, reduce costs, expand access, and align commercial success with lasting therapeutic value. On the CDMO side, it partners with 15 of the top 20 global pharmaceutical and biotechnology firms, many of which have collaborated for ten to 20 years, reinforcing continuous process improvement and optimized outcomes.
Sustained Growth Built on Trust
How do long-term partnerships and process investment sustain growth in pharmaceutical manufacturing?
The company frequently invests upfront in process development, R&D, and technical consulting to ensure that drug manufacturing is precise, scalable, and reliable for its clients. This science-first approach has supported uninterrupted operations for more than 30 years without intellectual property disputes and has reinforced trust in both quality and governance. Today, approximately 80 percent of its projects serve clients outside mainland China, with deep engagement across North America, Europe, Japan, and South America.
Tianyu’s long-term collaborations with leading pharmaceutical and biotechnology companies ensure a consistent supply across chronic disease and oncology programs. As these therapeutic areas evolve, the company leverages its process expertise and integrated manufacturing to ensure reliable scale-up, positioning itself as a trusted API partner globally.
Advancing Global Supply in Chronic Disease and Oncology APIs
Executives responsible for sourcing chronic disease and anti-cancer drug ingredients face a market defined by scientific complexity, regulatory scrutiny and mounting pressure to control cost without compromising quality. Hypotensive, hypoglycemic and oncology portfolios require manufacturing partners that can translate intricate chemistry into consistent commercial output across multiple jurisdictions. Timelines are rarely forgiving. Scaleup failures, quality gaps or weak documentation can delay approvals and erode competitive advantage.
Long-term success in this environment depends on a supplier’s scientific depth and its ability to carry process knowledge from early development through commercial production without disruption. An organization grounded in experienced chemists and structured research teams is better positioned to refine synthetic routes, adapt to emerging modalities and address the challenges of peptides, antibody-drug conjugate linkers and other complex molecules. Stable R&D leadership and low turnover reduce the risk of knowledge loss during tech transfer.
Control over raw materials and key starting materials has become another defining factor. End-to-end oversight of inputs allows tighter management of impurity profiles and reproducibility, particularly critical for oncology compounds and chronic disease therapies that demand high purity and consistent batch performance. Suppliers that invest heavily in analytical infrastructure and quality systems, and that integrate process development teams directly with production, tend to mitigate scale-up risk more effectively. Direct handoff between non-GMP optimization and GMP manufacturing, supported by strong in situ monitoring and digital controls, reduces variability and shortens development cycles.
Regulatory alignment across global markets further distinguishes capable partners. Active audits from the FDA, EMA and other major authorities test the maturity of quality systems. Regular inspections, comprehensive QA and QC staffing and dedicated laboratory capacity provide assurance that documentation and compliance will withstand scrutiny. For buyers planning multi-country launches or lifecycle expansions, experience in filing drug master files and managing approvals in dozens of jurisdictions adds strategic value.
Supply continuity and capacity flexibility are equally decisive. Multi-site manufacturing footprints, built-in redundancy across workshops and lines, and significant reactor volume create options when demand shifts or unforeseen disruptions occur. Temperature-controlled storage, packaging capabilities and distribution experience across international markets support uninterrupted supply, particularly important for chronic therapies and oncology regimens where shortages have serious consequences.
Cost discipline must also be grounded in process efficiency rather than short-term concessions. Continuous flow adaptation, reagent recovery and optimized reaction conditions can lower production expense while preserving quality. Sustainable practices that recycle catalysts or reduce waste not only improve margins but also strengthen long-term partnerships in an industry increasingly attentive to environmental performance.
Tianyu Pharm reflects many of these characteristics. The company has operated for three decades and employs more than 4,000 personnel, including over 200 PhDs guiding process and formulation development. Six specialized R&D laboratories, six manufacturing sites, and reactor capacity capable of supporting projects from lab scale to commercial volumes support the company's efforts. Each site includes extensive QA and QC facilities, and a recent FDA inspection concluded with corrective actions successfully addressed. The company has filed DMFs in multiple countries and derives a majority of its business from international markets.
For executives evaluating chronic disease and oncology API suppliers, Tianyu Pharm stands out as a premier choice. Its integrated model links development scientists directly to production, its internal control of starting materials strengthens quality consistency, and its global regulatory experience supports market entry across regions. The company is strategically expanding into highpotency manufacturing, peptides, and ADC components to align with emerging oncology needs. Taken together, these capabilities position it as a dependable partner for sustained global supply.
...Read more
Chronic Disease and Anti Cancer Drugs Supplier Info
Q1
What led Tianyu Pharmaceutical to be recognized among top chronic disease and anti-cancer drugs suppliers?
Zhejiang Tianyu Pharmaceutical Co., Ltd. has gained global recognition as a Chronic Disease and Anti-Cancer Drugs Supplier due to its large-scale manufacturing capabilities and integrated pharmaceutical expertise. Founded in 1993, the company specializes in APIs, intermediates and formulations, supplying products to over 70 countries and serving more than 1,000 customers worldwide. Its strong portfolio includes therapies for hypertension, diabetes, lipid disorders and oncology, positioning it as a key supplier in both chronic disease and anti-cancer segments.
Q2
How does Tianyu Pharmaceutical differentiate its approach to pharmaceutical supply?
An end-to-end development and manufacturing model defines how Tianyu operates as a Chronic Disease and Anti-Cancer Drugs Supplier. The company offers one-stop services from clinical phase I through commercial production, integrating process R&D, API manufacturing, formulation development and regulatory support. This seamless approach reduces fragmentation in the drug development pipeline and enables faster, more efficient product delivery.
Q3
How does Tianyu support global pharmaceutical partners?
Tianyu supports partners by providing comprehensive CDMO and API services tailored to both originator and generic pharmaceutical companies. Its capabilities include analytical development, stability studies, regulatory filings and commercial-scale manufacturing under cGMP conditions. By combining technical expertise with regulatory compliance across major global agencies, the company ensures that its role as a Chronic Disease and Anti-Cancer Drugs Supplier aligns with international standards.
Q4
What value do Tianyu’s products bring to healthcare and drug development?
Scalability, quality and therapeutic breadth define the value of Tianyu as a Chronic Disease and Anti-Cancer Drugs Supplier. Its products support treatment areas such as cardiovascular disease, metabolic disorders and oncology, which represent some of the highest global disease burdens. By delivering high-quality APIs and formulations at scale, the company enables pharmaceutical firms to bring essential therapies to market efficiently and cost-effectively.
Q5
What role do technology and R&D play in Tianyu’s operations?
Advanced R&D and process innovation are central to Tianyu’s position as a Chronic Disease and Anti-Cancer Drugs Supplier. The company operates multiple R&D centers with significant investment in analytical instruments and employs hundreds of scientists, including PhD-level researchers. Its expertise spans complex chemical synthesis technologies, enzyme-based reactions and continuous flow chemistry, enabling the development of high-quality and scalable pharmaceutical products.
Q6
Why is Tianyu Pharmaceutical relevant to current global pharmaceutical needs?
The increasing demand for affordable, high-quality treatments for chronic diseases and cancer has elevated the importance of reliable suppliers, and Tianyu addresses this need as a Chronic Disease and Anti-Cancer Drugs Supplier. Its ability to combine global regulatory compliance, large-scale production and end-to-end development services aligns with the evolving needs of pharmaceutical companies seeking efficient and scalable supply partners.
